Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Cancer

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2010.12.015PMID 21257306PMCID PMC3073413
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

  2010cited by this paper
• Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

  2009cited by this paper
• Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

  2009cited by this paper
• 5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study)

  2009cited by this paper
• Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

  2009cited by this paper
• Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

  2009cited by this paper
• A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

  2009cited by this paper
• Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective

  2008cited by this paper
• Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

  2008cited by this paper
• End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

  2007cited by this paper
• Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

  2007cited by this paper
• Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

  2007cited by this paper
• Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

  2006cited by this paper
• Capecitabine as adjuvant treatment for stage III colon cancer.

  2005cited by this paper
• Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Validation of surrogate end points in multiple randomized clinical trials with failure time end points

  2001cited by this paper
• Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

  1990cited by this paper

• Dormancy in Colorectal Cancer: The Functional Core of Resistance, Metastasis, and Relapse.

  2025cites this paper
• Adjuvant therapy guided by molecular classification in endometrial cancer: survival benefit and safety profile.

  2025cites this paper
• Number of Lymph Nodes Examined as a Prognosis Factor in Patients With Stage II or III Colon Cancer.

  2025cites this paper
• Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months.

  2024cites this paper
• The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses

  2024cites this paper
• Navigating treatment options for sacral spine lymphoma: A medical journey

  2023influential citation
• Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers

  2023cites this paper
• pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients—An Updated Pooled Analysis of Eleven International Randomized Trials

  2023cites this paper
• Association between event-free survival and overall survival in early-stage triple-negative breast cancer.

  2023cites this paper
• Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan.

  2022cites this paper
• Total neoadjuvant therapy in rectal cancer

  2022cites this paper
• A Predictive Model of 2yDFS During MR-Guided RT Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients

  2022cites this paper
• Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: analysis of aggregated data from a systematic literature review.

  2022cites this paper
• Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis.

  2022cites this paper
• Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial

  2022cites this paper
• The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy

  2022cites this paper
• Longitudinal assessment of ROPRO as an early indicator of overall survival in oncology clinical trials: a retrospective analysis

  2022influential citation
• Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma

  2022cites this paper
• Qu-Yu-Jie-Du Decoction Inhibits the Recurrence and Metastasis of Stage III Colorectal Cancer by Targeting Inflammatory Pathways: A Retrospective Clinical Study

  2022cites this paper
• Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer

  2021cites this paper
• Methoden klinischer Prüfung in der Onkologie

  2021cites this paper
• Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset

  2021cites this paper
• Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease

  2021cites this paper
• Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.

  2021cites this paper
• Surrogate Endpoints in Oncology: Overview of Systematic Reviews and Their Use for Health Decision Making in Mexico.

  2021cites this paper
• Neoadjuvant and adjuvant end-points in health technology assessment in oncology.

  2021cites this paper
• Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

  2021cites this paper
• Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

  2020cites this paper
• Outcome measures in multimodal rectal cancer trials: Which endpoints should we use?

  2020cites this paper
• Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future

  2020cites this paper
• Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints.

  2020cites this paper
• Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)

  2020cites this paper
• Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints.

  2020cites this paper
• Outcome measures in multimodal rectal cancer trials.

  2020cites this paper
• Deep Convolutional Neural Network-Based Lymph Node Metastasis Prediction for Colon Cancer Using Histopathological Images

  2020cites this paper
• Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer

  2020cites this paper
• Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA Phase 3 Randomized Trial.

  2020cites this paper
• Adjuvant Chemotherapy for Stage II Colon Cancer

  2020cites this paper
• Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1

  2020cites this paper
• Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions

  2020cites this paper
• Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.

  2019cites this paper
• Making sense of adjuvant chemotherapy in colorectal cancer.

  2019cites this paper
• A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.

  2019cites this paper
• Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer

  2019cites this paper
• A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma

  2019cites this paper
• Circulating biomarkers as prognostic and predictive markers in rectal cancer

  2019cites this paper
• Changing paradigms in adjuvant treatment of colorectal cancer.

  2018cites this paper
• Frequency of Mismatch Repair Protein Deficiency in a Puerto Rican Population with Colonic Adenoma and Adenocarcinoma

  2018cites this paper
• What is the optimal duration of adjuvant therapy in colon cancer?

  2017cites this paper
• Exploring the medication duration based on the effect of traditional Chinese medicine on postoperative stage I-III colorectal patients: a retrospective cohort study

  2017cites this paper
• Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.

  2017cites this paper
• Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.

  2017cites this paper
• Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.

  2017cites this paper
• Texture Analysis of Abnormal Cell Images for Predicting the Continuum of Colorectal Cancer

  2017cites this paper
• Volumetric Versus Unidimensional Measures of Metastatic Colorectal Cancer in Assessing Disease Response

  2017cites this paper
• Comparison of Contrast-Enhanced CT and [18F]FDG PET/CT Analysis Using Kurtosis and Skewness in Patients with Primary Colorectal Cancer

  2017cites this paper
• Treatment effect quantification for time‐to‐event endpoints–Estimands, analysis strategies, and beyond

  2017cites this paper
• Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

  2016cites this paper
• Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer

  2016cites this paper
• Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials

  2016cites this paper
• Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

  2016cites this paper
• Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting.

  2016cites this paper
• Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

  2016cites this paper
• Physical activity, social support and participation of women knowledge about cervical cancer screening, the screening attitude multiplicative influence of cervical cancer screening

  2016cites this paper
• A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

  2016cites this paper
• Adjuvant chemotherapy for rectal cancer.

  2015cites this paper
• The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)

  2015cites this paper
• Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance.

  2015cites this paper
• 2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

  2015cites this paper
• The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

  2015cites this paper
• Epidermal growth factor receptor in CRC patients in the era of the RAS.

  2015cites this paper
• Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.

  2015cites this paper
• Adjuvant chemotherapy for rectal cancer.

  2015cites this paper
• Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

  2015cites this paper
• CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes

  2015cites this paper
• Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial.

  2015cites this paper
• XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy

  2015cites this paper
• Non-inferiority trials: why oncologists must remain wary.

  2015cites this paper
• Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

  2015cites this paper
• Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients.

  2015cites this paper
• A DJUVANT THERAPY FOR COLORECTAL CANCER

  2014cites this paper
• Prognostic Significance and Molecular Mechanism of ATP-Binding Cassette Subfamily C Member 4 in Resistance to Neoadjuvant Radiotherapy of Locally Advanced Rectal Carcinoma

  2014cites this paper
• Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study

  2014cites this paper
• Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients

  2014cites this paper
• Synthesis and antitumor activities of novel rhein α-aminophosphonates conjugates.

  2014cites this paper
• Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration

  2014cites this paper
• A path for diagnosis and therapy of colon cancer: a continuous quality improvement.

  2014cites this paper
• ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

  2014cites this paper
• New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials.

  2013cites this paper
• Adjuvant therapy of stage III colon cancer.

  2013cites this paper
• Mining the ACCENT database: a review and update.

  2013cites this paper
• Adjuvant and Neoadjuvant Therapy for Gastric Cancer

  2013cites this paper
• Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival.

  2013cites this paper
• Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer.

  2013cites this paper
• Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer

  2013cites this paper
• Clinically relevant study end points in rectal cancer.

  2012cites this paper
• Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial

  2012cites this paper
• The role of biological agents in the resection of colorectal liver metastases.

  2012cites this paper
• Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib

  2012cites this paper
• Do Different Populations of Rectal Cancer Exist

  2012cites this paper